Develops buntanetap and other drug candidates for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative conditions.
10-K for FY2025, filed Mar 13, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 13, 2026
8-K, filed Oct 30, 2026
On October 29, 2026, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it…View ↗
Added a dementia program
The latest pipeline includes buntanetap for Parkinson’s disease dementia, while the older report described the chronic-neurodegeneration program as covering Alzheimer’s and Parkinson’s diseases.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 13, 2026Our pipeline consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301…View ↗
Our pipeline consists of: buntanetap for chronic neurodegeneration - including AD, PD and PDD - as well as within certain combination…View ↗
Competes with Exenatide
10-K for FY2025, filed Mar 13, 2026So far, we believe that only buntanetap and Exenatide are in the later stages of clinical development for disease-modification, and no…View ↗
Loading...